Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy

Cancer. 2022 May 1;128(9):1724-1726. doi: 10.1002/cncr.34158. Epub 2022 Feb 25.
No abstract available

Keywords: aromatase inhibitor; breast cancer; endocrine therapy duration; low ER+; tamoxifen.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use
  • Aromatase Inhibitors / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Duration of Therapy
  • Female
  • Humans
  • Receptors, Estrogen*
  • Tamoxifen / therapeutic use

Substances

  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Receptors, Estrogen
  • Tamoxifen

Associated data

  • ClinicalTrials.gov/NCT00003678
  • ClinicalTrials.gov/NCT02531516